Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.
Songpajeil Orthopedic Clinic, Seoul, South Korea.
Dermatol Ther. 2021 Nov;34(6):e15168. doi: 10.1111/dth.15168. Epub 2021 Oct 26.
With the increasing demand for body contouring, botulinum toxin (BTX) injection is being widely used off-label for muscular hypertrophy. However, to the best of our knowledge, no study has investigated the clinical efficacy of BTX type A (BTX-A) in deltoid muscle hypertrophy. This study was conducted to evaluate the efficacy and safety of intramuscular injection of BTX in reducing deltoid muscle hypertrophy. Overall, 10 patients with bilateral deltoid muscle hypertrophy were treated with an intramuscular injection of prabotulinum toxin A, with a total of 50 units [U] administered per patient. As measured by ultrasonography, the thickness of the deltoid muscles was significantly decreased at weeks 2 and 12. In addition, the clinical assessment score by blinded investigators was improved after the treatment; however, patients' satisfaction scores were relatively low. No major complications were reported. Therefore, intramuscular injection of BTX-A seems to be a candidate for novel treatment option for deltoid muscle hypertrophy. Further larger clinical studies are warranted to confirm the efficacy of BTX-A.
随着对身体塑形的需求不断增加，肉毒毒素（BTX）注射已被广泛应用于肌肉肥大的非适应证治疗。然而，据我们所知，尚无研究调查 BTX-A 型（BTX-A）在三角肌肥大中的临床疗效。本研究旨在评估肌肉内注射 BTX 减少三角肌肥大的疗效和安全性。总体而言，10 例双侧三角肌肥大患者接受了肉毒梭菌毒素 A 的肌肉内注射治疗，每位患者共注射 50 单位[U]。超声检查结果显示，三角肌厚度在 2 周和 12 周时显著减少。此外，经盲法研究者评估，治疗后临床评估评分得到改善；但患者满意度评分相对较低。未报告重大并发症。因此，BTX-A 肌肉内注射似乎是三角肌肥大的一种新型治疗选择。需要进一步开展更大规模的临床研究来证实 BTX-A 的疗效。
